Glycan Database
Ireland?s National Institute for Bioprocessing Research and Training (NIBRT) and Waters have announced a collaboration that will create the first database for glycan analysis by UPLC.
During the manufacture of biomolecules correct glycosylation is essential for the protein to achieve the correct structure and therapeutic efficacy. This process can be strongly influenced by many environmental factors during cell culture, such as dissolved oxygen, pH, carbon source and temperature. Given the number of possible glycan structures that can attach to a protein, it can be time-consuming to identify and quantify them all. This is why Ireland’s National Institute for Bioprocessing Research and Training (NIBRT) and Waters have announced a collaboration that will create the first database for glycan analysis by UPLC. Expected to be available in 2011, NIBRT will develop, maintain and license the database while Waters and NIBRT will co-market it worldwide.
“By combining our know-how in separations and glycan analysis with NIBRT’s expertise in glycobiology we can make fast and accurate glycosylation analysis a reality for the makers of biotherapeutics,” said Dr Jeff Mazzeo, director of biopharmaceutical business operations at Waters, in a statement. “Our goal is to simplify and introduce more certainty into the process of analyzing glycans and making quality biomolecules.”
For more information visit www.waters.com
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
